Skip to main content

Table 1 Oral anti-inflammatory agents for relapsing-remitting multiple sclerosis (RRMS).

From: Recent developments in multiple sclerosis therapeutics

Agent Proposed mechanisms of action Stage of development*
Fingolimod (FTY 720) Binds sphingosine-1-phosphate on T cells preventing circulation and CNS entry Phase III for RRMS
Cladribine Selectively depletes B and T cells by causing DNA damage Phase III for RRMS and CIS
Laquinimod Shifts T cells from TH1 (pro-inflammatory) to TH2 (anti-inflammatory) Phase III
Teriflunomide Shifts T cells from TH1 (pro-inflammatory) to TH2 (anti-inflammatory); Blocks pyrimidine and reproduction of rapidly dividing B and T cells Phase III for RRMS and CIS
BG00012 (dimethyl fumarate) Antioxidant Phase III
  1. *compiled from clinicaltrials.gov
  2. CIS, clinically isolated syndrome; CNS, central nervous system